We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Multivitamin and Niacin can interact. Therapeutic niacin doses far exceed multivitamin contributions. The primary interaction concern is additive hepatotoxicity risk when combining high-dose niacin (especially extended-release) with multivitamins containing additional hepatotoxic-risk nutrients (vitamin A, iron). SAMe depletion may reduce methylation capacity. At therapeutic niacin doses (500mg+), the multivitamin niacin content is negligible. The clinical concern is avoiding additional hepatotoxic supplements (excess vitamin A, iron) concurrent with therapeutic niacin. Monitor liver function tests every 3–6 months with therapeutic niacin use. Ensure adequate methyl donor support (B12, folate, choline) to compensate for niacin methylation demand.
Therapeutic niacin doses far exceed multivitamin contributions. The primary interaction concern is additive hepatotoxicity risk when combining high-dose niacin (especially extended-release) with multivitamins containing additional hepatotoxic-risk nutrients (vitamin A, iron). SAMe depletion may reduce methylation capacity.
Multivitamins contain 14–35mg niacin (niacinamide or nicotinic acid). Therapeutic niacin supplements are dosed at 500–2000mg/day for lipid modification. This creates a massive disparity in intake. Immediate-release nicotinic acid above 35mg triggers prostaglandin D2-mediated cutaneous vasodilation (flushing). Above 500mg/day, hepatotoxicity risk emerges (particularly with extended-release formulations). Niacin also inhibits PARP, an NAD+-consuming DNA repair enzyme, at high doses and depletes methyl groups via SAMe-dependent methylation of nicotinamide metabolites.
What to do: At therapeutic niacin doses (500mg+), the multivitamin niacin content is negligible. The clinical concern is avoiding additional hepatotoxic supplements (excess vitamin A, iron) concurrent with therapeutic niacin. Monitor liver function tests every 3–6 months with therapeutic niacin use. Ensure adequate methyl donor support (B12, folate, choline) to compensate for niacin methylation demand.
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.